Form 8-K - Current report:
SEC Accession No. 0001193125-24-257237
Filing Date
2024-11-13
Accepted
2024-11-13 16:21:00
Documents
19
Period of Report
2024-11-13
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d896495d8k.htm   iXBRL 8-K 27558
2 EX-23.1 d896495dex231.htm EX-23.1 1506
3 EX-23.2 d896495dex232.htm EX-23.2 1829
4 EX-99.1 d896495dex991.htm EX-99.1 421980
5 EX-99.2 d896495dex992.htm EX-99.2 37901
9 GRAPHIC g896495g36e52.jpg GRAPHIC 30415
10 GRAPHIC g896495g91o34.jpg GRAPHIC 37439
  Complete submission text file 0001193125-24-257237.txt   778156

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA slrn-20241113.xsd EX-101.SCH 2842
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE slrn-20241113_lab.xml EX-101.LAB 17979
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE slrn-20241113_pre.xml EX-101.PRE 11253
21 EXTRACTED XBRL INSTANCE DOCUMENT d896495d8k_htm.xml XML 3633
Mailing Address 4149 LIBERTY CANYON RD. AGOURA HILLS CA 91301
Business Address 4149 LIBERTY CANYON RD. AGOURA HILLS CA 91301 805-871-4300
ACELYRIN, Inc. (Filer) CIK: 0001962918 (see all company filings)

EIN.: 852406735 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41696 | Film No.: 241454618
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)